ArticleAnalytical science advances2020
Dual sensitivity enhancement in gold nanoparticle-based lateral flow immunoassay for visual detection of carcinoembryonic antigen.
Article in Analytical science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Early diagnosis of pancreatic ductal adenocarcinoma by signal-enhanced lateral flow immunoassay: SELFI.Nature communications · 2026Article
- Gold Nanotapes and Nanopinecones in a Quantitative Lateral Flow Assay for the Cancer Biomarker Carcinoembryonic Antigen.ACS applied nano materials · 2023Article
- Research Progress and Future Trends of Microfluidic Paper-Based Analytical Devices in In-Vitro Diagnosis.Biosensors · 2022Review
- Point-of-care system for rapid real-time detection of SARS-CoV-2 virus based on commercially available Arduino platforms.Frontiers in bioengineering and biotechnology · 2022Article
- On-Site Detection of Carcinoembryonic Antigen in Human Serum.Biosensors · 2021Article
- Article
- Comparative Study of In Situ Techniques to Enlarge Gold Nanoparticles for Highly Sensitive Lateral Flow Immunoassay of SARS-CoV-2.Biosensors · 2021Article
- Dual sensitivity enhancement in gold nanoparticle-based lateral flow immunoassay for visual detection of carcinoembryonic antigen.Analytical science advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we presented the development of cost-effective dual sensitivity enhancement in gold nanoparticle-based lateral flow test strip for detection of carcinoembryonic antigen. On the one hand, we employed protein G as a host matrix for oriented immobilization of antibodies within the nitrocellulose membrane. On the other hand, we utilized gold enhancement approach to visualize the final signals effectively. Primary examinations revealed that the smaller sized nanoparticles have greater signal enhancement compared to bigger ones. So, mono-dispersed gold nanoparticles with average diameters of 11.40 ± 1.40 nm were utilized as tags. The measurement of fluorescent intensity of FITC-tagged secondary antibody attached to the polyclonal antibody, in the presence/absence of protein G as a host matrix on microplate wells, showed the successful oriented immobilization of antibodies via the host matrix. The FESEM images confirmed the attachment and growth of nanoparticles within the porous nitrocellulose membrane, after gold enhancement. Finally, under the optimized conditions, the developed strip could quantify the standard values of target within 2-50 ng/mL range with a limit of detection of 0.35 ng/mL. This strategy enabled the reduction of antibody consumption from a conventional amount of 0.6 µg/strip down to 0.012 µg/strip. The serum samples containing carcinoembryonic antigen were also successfully analyzed by the developed strip with a visual detection limit of 10 ng/mL, which confirms favorable characteristics of the developed test strip for point-of-care applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.